Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: HardToFind who wrote (12455)	11/25/2019 11:07:46 AM
From: drkaz	Read Replies (1) \| Respond to of 12873

Minimum: 6 years (assuming Diwan can find another patsy to pay $50 Mn for developing it) I would suggest taking the average of several estimates. Anybody else want to give it a WAG? Can't say I disagree much. They might be able to get the animal portion of it done in a year rather than two - and it would be a different sort of toxicity study if the 'Noroviricide' needs to be ingested or IV administered,... Although IF by that point the Shingles-cide is on the market - then they should be able to self-fund further development rather than 'finding a patsy'.